Edwards Lifesciences Co. (NYSE:EW) Holdings Trimmed by Federated Hermes Inc.

Federated Hermes Inc. lowered its holdings in Edwards Lifesciences Co. (NYSE:EW) by 84.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,003 shares of the medical research company’s stock after selling 10,491 shares during the period. Federated Hermes Inc.’s holdings in Edwards Lifesciences were worth $153,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $34,000. Operose Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares during the period. SRS Capital Advisors Inc. grew its position in Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. acquired a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $52,000. Finally, ORG Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $66,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on EW. Oppenheimer increased their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Citigroup upped their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Stifel Nicolaus raised their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Insider Buying and Selling

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the sale, the director now directly owns 4,486 shares of the company’s stock, valued at $380,278.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $86.45, for a total value of $609,991.20. Following the transaction, the director now directly owns 26,980 shares in the company, valued at $2,332,421. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the sale, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $380,278.22. The disclosure for this sale can be found here. Insiders sold 237,749 shares of company stock valued at $20,920,934 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.2 %

Shares of EW stock opened at $85.25 on Monday. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The stock has a fifty day moving average price of $90.08 and a 200 day moving average price of $79.46. The stock has a market cap of $51.37 billion, a P/E ratio of 36.75, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.